Natus Medical Incorporated (NASDAQ:BABY) Position Boosted by Thrivent Financial For Lutherans
Thrivent Financial For Lutherans raised its stake in Natus Medical Incorporated (NASDAQ:BABY) by 5.3% during the first quarter, according to its most recent filing with the SEC. The firm owned 18,570 shares of the medical equipment provider’s stock after buying an additional 930 shares during the period. Thrivent Financial For Lutherans’ holdings in Natus Medical were worth $729,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also modified their holdings of BABY. Columbia Wanger Asset Management LLC boosted its stake in Natus Medical by 243.6% in the first quarter. Columbia Wanger Asset Management LLC now owns 2,030,207 shares of the medical equipment provider’s stock worth $79,686,000 after buying an additional 1,439,382 shares in the last quarter. Wellington Management Group LLP boosted its stake in Natus Medical by 105.7% in the first quarter. Wellington Management Group LLP now owns 1,795,094 shares of the medical equipment provider’s stock worth $70,457,000 after buying an additional 922,268 shares during the period. Norges Bank bought a new stake in Natus Medical during the fourth quarter worth approximately $11,560,000. United Services Automobile Association bought a new stake in Natus Medical during the first quarter worth approximately $3,907,000. Finally, Legato Capital Management LLC boosted its stake in Natus Medical by 3,825.0% in the first quarter. Legato Capital Management LLC now owns 99,695 shares of the medical equipment provider’s stock worth $2,540,000 after buying an additional 97,155 shares during the period. Institutional investors own 93.86% of the company’s stock.
Shares of Natus Medical Incorporated (BABY) traded down 2.46% during midday trading on Tuesday, reaching $33.70. 480,827 shares of the company traded hands. Natus Medical Incorporated has a 1-year low of $33.15 and a 1-year high of $44.39. The stock has a market capitalization of $1.10 billion, a P/E ratio of 59.23 and a beta of 0.93. The stock’s 50-day moving average is $36.71 and its 200-day moving average is $36.85.
Natus Medical (NASDAQ:BABY) last posted its quarterly earnings results on Wednesday, July 26th. The medical equipment provider reported $0.34 EPS for the quarter, beating the consensus estimate of $0.33 by $0.01. The firm had revenue of $122.20 million during the quarter, compared to analysts’ expectations of $121.99 million. Natus Medical had a return on equity of 12.09% and a net margin of 4.20%. The company’s revenue for the quarter was up 27.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.39 EPS. Equities analysts predict that Natus Medical Incorporated will post $1.70 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Natus Medical Incorporated (NASDAQ:BABY) Position Boosted by Thrivent Financial For Lutherans” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/08/natus-medical-incorporated-nasdaqbaby-stake-raised-by-thrivent-financial-for-lutherans-updated-updated-updated.html.
A number of analysts recently commented on the stock. Benchmark Co. reiterated a “buy” rating and issued a $48.00 target price (down from $55.00) on shares of Natus Medical in a research note on Monday, May 1st. Zacks Investment Research lowered shares of Natus Medical from a “hold” rating to a “sell” rating in a research report on Friday, April 28th. BidaskClub raised shares of Natus Medical from a “sell” rating to a “hold” rating in a research report on Saturday, July 1st. Finally, TheStreet lowered shares of Natus Medical from a “b” rating to a “c+” rating in a research report on Thursday, April 27th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $45.00.
In other news, Director Doris Engibous sold 5,000 shares of the stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $32.68, for a total value of $163,400.00. Following the completion of the transaction, the director now directly owns 22,650 shares of the company’s stock, valued at approximately $740,202. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider James B. Hawkins bought 4,000 shares of the company’s stock in a transaction dated Thursday, June 15th. The stock was bought at an average cost of $33.98 per share, with a total value of $135,920.00. Following the completion of the acquisition, the insider now owns 578,023 shares in the company, valued at approximately $19,641,221.54. The disclosure for this purchase can be found here. Corporate insiders own 5.50% of the company’s stock.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Stock Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related stocks with our FREE daily email newsletter.